Trial Profile
Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms PrEP Demonstration Project
- 19 Mar 2020 Results assessing whether Quarterly STI screening among HIV pre-exposure prophylaxis (PrEP) could prevent a substantial number of partners from being exposed to asymptomatic STIs and decrease transmission, published in the AIDS
- 04 Oct 2017 Results assessing kidney function in individuals in expanding PrEP roll-out cohort treated with emtricitabine/tenofovir disoproxil fumarate, were published in the JAIDS.
- 08 Aug 2013 Planned End Date changed from 1 Aug 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.